Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics Inc (NQ: ALGS )

0.5399 -0.0001 (-0.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,049
Open 0.5400
Bid (Size) 0.5222 (20)
Ask (Size) 0.5400 (39)
Prev. Close 0.5400
Today's Range 0.5147 - 0.5501
52wk Range 0.3482 - 1.200
Shares Outstanding 42,940,089
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
From Aligos Therapeutics
Via GlobeNewswire

Performance

YTD
-23.89%
-23.89%
1 Month
+33.97%
+33.97%
3 Month
-34.00%
-34.00%
6 Month
-22.87%
-22.87%
1 Year
-40.31%
-40.31%

More News

Read More
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
From Aligos Therapeutics
Via GlobeNewswire
Recap: Aligos Therapeutics Q4 Earnings
Via Benzinga
Aligos Therapeutics Earnings Preview
Via Benzinga
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
From Aligos Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
From Aligos Therapeutics
Via GlobeNewswire
Earnings Scheduled For March 12, 2024
Via Benzinga
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
From Aligos Therapeutics
Via GlobeNewswire
Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.